New molecular classifications of breast cancer
- PMID: 19729680
- DOI: 10.3322/caac.20029
New molecular classifications of breast cancer
Abstract
Traditionally, pathologic determinations of tumor size, lymph node status, endocrine receptor status, and human epidermal growth factor receptor 2 (HER2) status have driven prognostic predictions and adjuvant therapy recommendations for patients with early stage breast cancer. However, these prognostic and predictive factors are relatively crude measures, resulting in many patients being overtreated or undertreated. As a result of gene expression assays, there is growing recognition that breast cancer is a molecularly heterogeneous disease. Evidence from gene expression microarrays suggests the presence of multiple molecular subtypes of breast cancer. The recent commercial availability of gene expression profiling techniques that predict risk of disease recurrence as well as potential chemotherapy benefit have shown promise in refining clinical decision making. These techniques will be reviewed in this article.
(c) 2009 American Cancer Society, Inc.
Similar articles
-
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Adv Anat Pathol. 2009. PMID: 19546609 Review.
-
Commercialized multigene predictors of clinical outcome for breast cancer.Oncologist. 2008 May;13(5):477-93. doi: 10.1634/theoncologist.2007-0248. Oncologist. 2008. PMID: 18515733 Review.
-
Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.Expert Rev Mol Diagn. 2007 May;7(3):269-80. doi: 10.1586/14737159.7.3.269. Expert Rev Mol Diagn. 2007. PMID: 17489734 Review.
-
MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.Cancer Treat Rev. 2009 Jun;35(4):328-34. doi: 10.1016/j.ctrv.2008.12.002. Epub 2009 Jan 25. Cancer Treat Rev. 2009. PMID: 19171434 Review.
-
Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1019s-1023s. doi: 10.1158/1078-0432.CCR-05-2296. Clin Cancer Res. 2006. PMID: 16467119
Cited by
-
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.Exp Ther Med. 2012 Aug;4(2):231-236. doi: 10.3892/etm.2012.594. Epub 2012 May 30. Exp Ther Med. 2012. PMID: 23139713 Free PMC article.
-
Ordinal Logic Regression: A classifier for discovering combinations of binary markers for ordinal outcomes.Comput Stat Data Anal. 2015 Feb 1;82:152-163. doi: 10.1016/j.csda.2014.08.013. Comput Stat Data Anal. 2015. PMID: 25892835 Free PMC article.
-
Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea.Cancer Lett. 2011 Dec 15;312(1):82-90. doi: 10.1016/j.canlet.2011.08.003. Epub 2011 Aug 17. Cancer Lett. 2011. PMID: 21893382 Free PMC article.
-
Long intergenic non-coding RNA expression signature in human breast cancer.Sci Rep. 2016 Nov 29;6:37821. doi: 10.1038/srep37821. Sci Rep. 2016. PMID: 27897201 Free PMC article.
-
Metastasis inhibition in breast cancer by _targeting cancer cell extravasation.Breast Cancer (Dove Med Press). 2019 Apr 18;11:165-178. doi: 10.2147/BCTT.S166725. eCollection 2019. Breast Cancer (Dove Med Press). 2019. PMID: 31114313 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous